Cargando…

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective

Detalles Bibliográficos
Autor principal:	Sun, Wellington
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184954/ https://www.ncbi.nlm.nih.gov/pubmed/37198023 http://dx.doi.org/10.1016/j.vaccine.2023.05.008

Ejemplares similares

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
por: Gandy, Sam, et al.
Publicado: (2021)

Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination
por: Raccagni, Angelo Roberto, et al.
Publicado: (2022)

Efficacy of smallpox approved tecovirimat (Tpoxx) drug against Monkeypox: current update and futuristic prospects
por: Das, Tuyelee, et al.
Publicado: (2023)

Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules
por: Arasu, M.Valan, et al.
Publicado: (2023)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways
por: Klein, Kevin, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

The Current State of Pharma and the FDA: Approval of a Dementia Drug as a Case in Point
por: Eiser, Arnold R.
Publicado: (2021)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

In silico identification of potential inhibitors of vital monkeypox virus proteins from FDA approved drugs
por: Sahoo, Ajaya Kumar, et al.
Publicado: (2022)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Monkeypox outbreak in the post-eradication era of smallpox
por: Kandra, Naga Vishnu, et al.
Publicado: (2023)

The current emergence of monkeypox: The recurrence of another smallpox?
por: Lu, Tianyu, et al.
Publicado: (2022)

Human monkeypox and smallpox viruses: genomic comparison
por: Shchelkunov, Sergei N., et al.
Publicado: (2001)

Smallpox, Monkeypox and Other Human Orthopoxvirus Infections
por: Shchelkunova, Galina A., et al.
Publicado: (2022)

Why Should RNA Viruses Have All the Fun – Monkeypox, a Close Relative of Smallpox and a DNA Virus
por: Thakur, Suman, et al.
Publicado: (2022)

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
por: Borcoman, Edith, et al.
Publicado: (2020)

Monkeypox Epidemic: A Throwback From Smallpox Eradication
por: Bethineedi, Lakshmi Deepak, et al.
Publicado: (2022)

A narrative review of pox: smallpox vs monkeypox
por: Jayswal, Samiksha, et al.
Publicado: (2022)

Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak
por: Turner, Matthew, et al.
Publicado: (2022)

Is there any evidence for milder courses of monkeypox virus infections with childhood smallpox vaccination?
por: Hoffmann, Christian, et al.
Publicado: (2022)

Can a smallpox drug treat monkeypox? Compassionate use of tecovirimat for monkeypox infection
por: Fatima, Maurish, et al.
Publicado: (2023)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Frequency of Revaccination against Smallpox
por: Baron, Samuel, et al.
Publicado: (2003)

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications
por: Jain, Nityanand, et al.
Publicado: (2023)

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment
por: Ho, Cheryl, et al.
Publicado: (2022)

Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
por: Allegretti, Matteo, et al.
Publicado: (2018)

Monkeypox vaccine-related stigma
por: Mazzagatti, R., et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Vaccine hesitancy and other obstacles to COVID-19 control: lessons from smallpox
por: Davis, Robert
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Patient Safety Tools: SARS, Smallpox, Monkeypox, and Avian Flu
por: Fishman, Marlene, et al.
Publicado: (2005)

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections()
por: Baker, Robert O, et al.
Publicado: (2003)

FDA Coronavirus Treatment Acceleration Program: approved drugs and those in clinical trials
por: Nainwal, Lalit Mohan, et al.
Publicado: (2022)

Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
por: Beakes-Read, Ginny, et al.
Publicado: (2022)

USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nl9uequnmh1ete0rvvlt5uhveb